XTL Biopharmaceuticals company info

What does XTL Biopharmaceuticals do?
XTL Biopharmaceuticals ADR (TLV:XTLB), (NASDAQ:XTLB) focuses on the acquisition, development, and commercialization of pharmaceutical products for the treatment of autoimmune diseases. Their project pipeline mainly includes therapies aimed at conditions like systemic lupus erythematosus and multiple myeloma, showcasing a commitment to addressing hard-to-treat autoimmune disorders. The company's objectives are centered on advancing these projects through clinical trials towards regulatory approval, striving to meet unmet medical needs within these therapeutic areas. Their operations span from research and development to strategic partnerships aimed at enhancing their product portfolio and expanding their reach in the biopharmaceutical market.
XTL Biopharmaceuticals  company media
Company Snapshot

Is XTL Biopharmaceuticals a public or private company?

key
Ownership
Public

How many people does XTL Biopharmaceuticals employ?

people
Employees
3

What sector is XTL Biopharmaceuticals in?

pie chart
Sector
Health Care

Where is the head office for XTL Biopharmaceuticals ?

location pin
Head Office
Herzliya, Israel

What year was XTL Biopharmaceuticals founded?

founded flag
Year Founded
1993
What does XTL Biopharmaceuticals specialise in?
/Biopharmaceutical Development /Drug Research /Clinical Trials /Therapeutic Areas /Medicinal Products /Ongoing Projects

What are the products and/or services of XTL Biopharmaceuticals ?

Overview of XTL Biopharmaceuticals offerings
Development of hCDR1 (edratide) for the treatment of systemic lupus erythematosus, a potential therapy aimed at reducing symptoms and disease progression.
Research into therapies for multiple myeloma, focusing on small molecule drugs targeting specific pathways involved in the disease's progression.
Advancement of potential treatments for hepatitis C, through the exploration of novel antiviral compounds that could inhibit the virus's ability to replicate.
Investigation into autoimmune diseases, aiming to identify new therapeutic targets and develop innovative drugs to modulate the immune system.
Conducting clinical trials for advanced drug candidates in inflammatory diseases, with a focus on achieving significant improvements in patient outcomes and quality of life.
Collaboration with leading pharmaceutical companies and academic institutions to leverage cutting-edge research and development capabilities, enhancing the pipeline of therapies in various stages of development.

Who is in the executive team of XTL Biopharmaceuticals ?

XTL Biopharmaceuticals leadership team
  • Mr. Shlomo Spokone Shalev
    Mr. Shlomo Spokone Shalev
    CEO & Director
  • Mr. Itay  Weinstein
    Mr. Itay Weinstein
    Chief Financial Officer